Soleno Therapeutics (SLNO) Cash from Operations: 2013-2024
Historic Cash from Operations for Soleno Therapeutics (SLNO) over the last 12 years, with Dec 2024 value amounting to -$69.1 million.
- Soleno Therapeutics' Cash from Operations fell 35.87% to -$5.1 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$17.4 million, marking a year-over-year decrease of 48.72%. This contributed to the annual value of -$69.1 million for FY2024, which is 177.06% down from last year.
- Per Soleno Therapeutics' latest filing, its Cash from Operations stood at -$69.1 million for FY2024, which was down 177.06% from -$24.9 million recorded in FY2023.
- In the past 5 years, Soleno Therapeutics' Cash from Operations ranged from a high of -$20.8 million in FY2022 and a low of -$69.1 million during FY2024.
- In the last 3 years, Soleno Therapeutics' Cash from Operations had a median value of -$24.9 million in 2023 and averaged -$38.3 million.
- In the last 5 years, Soleno Therapeutics' Cash from Operations grew by 25.17% in 2022 and then tumbled by 177.06% in 2024.
- Yearly analysis of 5 years shows Soleno Therapeutics' Cash from Operations stood at -$25.2 million in 2020, then decreased by 10.09% to -$27.8 million in 2021, then increased by 25.17% to -$20.8 million in 2022, then declined by 20.01% to -$24.9 million in 2023, then slumped by 177.06% to -$69.1 million in 2024.